Post-earnings recap
Reported
Tue, Mar 2, 2010
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a loss per share that was worse than expected, which contributed to a decline in stock price by 1.88%. The absence of revenue figures and lack of guidance indicate uncertainty about the company's future performance. Investors may be cautious as the company focuses on its pipeline without clear direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.08 | N/A | -203.90% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance. They emphasized the importance of their ongoing projects but did not provide any forward guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on its pipeline and upcoming projects.